NextCure, Inc. (NXTC)
NMS – Real vaqt narxi. Valyuta: USD
7.81
+1.08 (16.05%)
Bozor ochiq: Aug 12, 2026, 3:18 PM EDT
6.76
+0.03 (0.48%)
Oldingi bozordan keyin: Aug 11, 2026, 7:45 PM EDT
Find any stock by ticker or company name

NMS – Real vaqt narxi. Valyuta: USD
7.81
+1.08 (16.05%)
Bozor ochiq: Aug 12, 2026, 3:18 PM EDT
6.76
+0.03 (0.48%)
Oldingi bozordan keyin: Aug 11, 2026, 7:45 PM EDT
NextCure, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, saratonni davolash uchun dori vositalarini ishlab chiqish bilan shug'ullanadi. Kompaniyaning mahsulot nomzodi LNCB74 bo'lib, bu B7-H4 ga yo'naltirilgan ADC bo'lib, u o'smalarni yo'q qilish uchun mo'ljallangan. Kompaniya, shuningdek, LAIR-1 orqali immunitetni bostirishni bloklash uchun mo'ljallangan LAIR-2 ning birlashgan oqsili NC410; o'tkir miyeloid leykemiya, blast hujayralari va leykemik ildiz hujayralariga yo'naltirilgan yangi LAIR-1 antitelasi NC525; Altsgeymer kasalligini davolash uchun ApoE4 ga yo'naltirilgan insonlashtirilgan antitelasi NC181; va Siglec-15 ga, shuningdek, osteoartrit va birikmaydigan sinishlar kabi surunkali suyak kasalliklariga yo'naltirilgan antitelasi NC605 ni ishlab chiqadi. Kompaniya, shuningdek, qattiq o'smalarni davolash uchun CDH6 (kadherin-6 yoki K-kadherin) ga yo'naltirilgan yangi antitel-dori konjugati (ADC) SIM0505 ni ishlab chiqadi. Kompaniya 2015 yilda ro'yxatga olingan va shtab-kvartirasi Beltsville, Merilendda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Lieping Chen M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Sebastien Maloveste Ph.D. | Senior Vice President of Business Development |
| Dr. Timothy Mayer Ph.D. | Chief Operating Officer |
| Dr. Udayan Guha M.D., Ph.D. | Chief Medical Officer |
| Mr. Kevin G. Shaw | Senior VP & General Counsel |
| Mr. Michael S. Richman MSBA | Co-Founder, CEO, President & Director |
| Mr. Sourav Kundu Ph.D. | Senior Vice President of Development & Manufacturing |
| Mr. Steven P. Cobourn CPA | Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-10 | 425 | tm2622749d1_425.htm |
| 2026-08-06 | 8-K | nxtc-20260806x8k.htm |
| 2026-08-04 | 425 | tm2622141d1_425.htm |
| 2026-07-16 | 425 | tm2620692d2_425.htm |
| 2026-07-14 | 425 | tm2620428d1_8k.htm |
| 2026-06-25 | 8-K | nxtc-20260618x8k.htm |
| 2026-06-01 | 8-K | nxtc-20260601x8k.htm |
| 2026-05-07 | 8-K | nxtc-20260507x8k.htm |
| 2026-05-07 | 10-Q | nxtc-20260331x10q.htm |
| 2026-04-24 | DEFA14A | tm261451d5_defa14a.htm |